[X] Close
You are about to erase all the values you have customized, search history, page format, etc.
Click here to RESET all values       Click here to GO BACK without resetting any value
Items 1 to 10 of about 36
1. Al-Faky YH, Al-Mosallam AR, Al-Rikabi AC, Al-Sohaibani MO: Medial canthus retiform hemangioendothelioma. Indian J Ophthalmol; 2014 Apr;62(4):491-3
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • We report here for the first time a case of medial canthus recurrent RH.
  • It may be helpful in our practice to include RH as a differential diagnosis of eyelid lesions.
  • It is noteworthy that the progressive course and recurrence tendency of RH might be misdiagnosed as angiosarcoma or basal cell carcinoma (BCC), if not expected and carefully evaluated by the pathologist.
  • [MeSH-major] Eyelid Neoplasms / diagnosis. Hemangioendothelioma / diagnosis. Ophthalmologic Surgical Procedures / methods. Reconstructive Surgical Procedures / methods. Skin Transplantation
  • [MeSH-minor] Child. Diagnosis, Differential. Female. Humans

  • Genetic Alliance. consumer health - Hemangioendothelioma.
  • MedlinePlus Health Information. consumer health - Plastic and Cosmetic Surgery.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Int J Clin Exp Pathol. 2010;3(5):528-33 [20606734.001]
  • [Cites] Arch Dermatol. 2010 Jul;146(7):758-63 [20644037.001]
  • [Cites] J Cutan Pathol. 2002 Apr;29(4):226-31 [12028155.001]
  • [Cites] Indian J Dermatol Venereol Leprol. 2009 Jan-Feb;75(1):60-2 [19172034.001]
  • [Cites] J Cutan Pathol. 2005 Oct;32(9):634-7 [16176302.001]
  • [Cites] Int J Dermatol. 2006 Jan;45(1):53-5 [16426378.001]
  • [Cites] Am J Dermatopathol. 2008 Feb;30(1):31-3 [18212541.001]
  • [Cites] Am J Surg Pathol. 1994 Feb;18(2):115-25 [8291650.001]
  • (PMID = 24817752.001).
  • [ISSN] 1998-3689
  • [Journal-full-title] Indian journal of ophthalmology
  • [ISO-abbreviation] Indian J Ophthalmol
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC4064231
  •  go-up   go-down


2. Qi XP, Ying RB, Ma JM, Liu WT, Du ZF, Fei J, Yang CP, Song QZ, Jin HY, Chen ZG, Han JS, Wang JQ, Chen XL, Zhao Y, Lu JJ, Zhang XN: Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma. Fam Cancer; 2012 Mar;11(1):131-6
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Case report: a p.C618S RET proto-oncogene germline mutation in a large Chinese pedigree with familial medullary thyroid carcinoma.
  • We report a Chinese pedigree with familial medullary thyroid carcinoma.
  • Direct sequencing of the entire coding sequences of Rearranged during Transfection (RET) identified a recurrent c.T1852A (p.C618S) mutation in 13 of 23 members.
  • Of the 13 carriers, seven (mean age: 42.6 years, range: 27-64) presented MTC as the isolated clinical phenotype, with elevated basal serum calcitonin (average: 1077.9 ng/L, range: 504-2,652) and a mean diameter of thyroid nodules of 2.97 cm (range: 1.6-4.3); they underwent a total thyroidectomy with modified bilateral/unilateral neck dissection and/or level VI lymph node dissection.
  • [MeSH-minor] Adolescent. Adult. Aged. Carcinoma, Medullary / congenital. Child. Female. Humans. Male. Middle Aged. Multiple Endocrine Neoplasia Type 2a. Pedigree. Phenotype. Thyroidectomy. Young Adult

  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] J Clin Endocrinol Metab. 2005 Nov;90(11):6232-6 [16118333.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5438-43 [14602786.001]
  • [Cites] Biomed Pharmacother. 2004 Jul-Aug;58(6-7):345-7 [15271413.001]
  • [Cites] Clin Endocrinol (Oxf). 2010 Oct;73(4):529-34 [20039896.001]
  • [Cites] J Med Genet. 2002 Apr;39(4):260-5 [11950855.001]
  • [Cites] Mol Cell Endocrinol. 2010 Jun 30;322(1-2):2-7 [20083156.001]
  • [Cites] J Korean Med Sci. 2010 Feb;25(2):226-9 [20119574.001]
  • [Cites] Oncologist. 2009 Jun;14(6):571-7 [19465682.001]
  • [Cites] J Clin Endocrinol Metab. 1997 Dec;82(12):4176-8 [9398735.001]
  • [Cites] PLoS One. 2011;6(5):e20353 [21655256.001]
  • [Cites] Fam Cancer. 2010 Sep;9(3):449-57 [20087666.001]
  • [Cites] Hum Mutat. 1997;9(2):97-109 [9067749.001]
  • [Cites] J Med Genet. 1999 Oct;36(10):771-4 [10528857.001]
  • [Cites] Cancer Res. 2003 Apr 15;63(8):1814-7 [12702567.001]
  • [Cites] Clin Endocrinol (Oxf). 2011 Feb;74(2):241-7 [21054478.001]
  • [Cites] Oncogene. 1994 Oct;9(10):3025-9 [8084609.001]
  • [Cites] JAMA. 1996 Nov 20;276(19):1575-9 [8918855.001]
  • [Cites] Thyroid. 2007 Feb;17(2):101-4 [17316110.001]
  • [Cites] Hum Mol Genet. 1993 Jul;2(7):851-6 [8103403.001]
  • [Cites] Fam Cancer. 2006;5(2):201-4 [16736292.001]
  • [Cites] Thyroid. 2009 Jun;19(6):565-612 [19469690.001]
  • [Cites] Proc Natl Acad Sci U S A. 1992 Mar 1;89(5):1616-20 [1542652.001]
  • [Cites] J Clin Endocrinol Metab. 2004 Jul;89(7):3579-84 [15240649.001]
  • (PMID = 22068382.001).
  • [ISSN] 1573-7292
  • [Journal-full-title] Familial cancer
  • [ISO-abbreviation] Fam. Cancer
  • [Language] eng
  • [Publication-type] Case Reports; Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] Netherlands
  • [Chemical-registry-number] EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; Familial medullary thyroid carcinoma
  •  go-up   go-down


3. Tarakji B, Baroudi K, Hanouneh S, Azzeghaiby SN, Nassani MZ: Possible recurrence of keratocyst in nevoid basal cell carcinoma syndrome: A review of literature. Eur J Dent; 2013 Sep;7(Suppl 1):S126-34
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Possible recurrence of keratocyst in nevoid basal cell carcinoma syndrome: A review of literature.
  • This review will highlight some current areas of difficulty or controversy in diagnosis and treatment of nevoid basal cell carcinoma syndrome (NBCCS).
  • This study has described the previous and the current outcomes of the treatment of OKC (recurrent cause).
  • Studies describing cohort, case series and miscellaneous clinical reports were retrieved and evaluated from 2010 to 2012.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 24966720.001).
  • [ISSN] 1305-7456
  • [Journal-full-title] European journal of dentistry
  • [ISO-abbreviation] Eur J Dent
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] India
  • [Other-IDs] NLM/ PMC4054071
  • [Keywords] NOTNLM ; Basal cell carcinomas / keratocyst / nevoid basal cell carcinoma syndrome
  •  go-up   go-down


Advertisement
4. Visuttijai K, Pettersson J, Mehrbani Azar Y, van den Bout I, Örndal C, Marcickiewicz J, Nilsson S, Hörnquist M, Olsson B, Ejeskär K, Behboudi A: Lowered Expression of Tumor Suppressor Candidate MYO1C Stimulates Cell Proliferation, Suppresses Cell Adhesion and Activates AKT. PLoS One; 2016;11(10):e0164063
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Lowered Expression of Tumor Suppressor Candidate MYO1C Stimulates Cell Proliferation, Suppresses Cell Adhesion and Activates AKT.
  • Myosin-1C (MYO1C) is a tumor suppressor candidate located in a region of recurrent losses distal to TP53.
  • We found a significant correlation between the tumor stage and lowered expression of MYO1C in endometrial carcinoma samples.
  • In cell transfection experiments, we found a negative correlation between MYO1C expression and cell proliferation, and MYO1C silencing resulted in diminished cell migration and adhesion.
  • Cells expressing excess of MYO1C had low basal level of phosphorylated protein kinase B (PKB, a.k.a.
  • [MeSH-major] Cell Adhesion / genetics. Cell Proliferation / genetics. Myosin Type I / genetics. Proto-Oncogene Proteins c-akt / genetics. Tumor Suppressor Proteins / genetics
  • [MeSH-minor] Cell Line, Tumor. Cell Movement / genetics. Cells, Cultured. HEK293 Cells. Humans. Phosphatidylinositol 3-Kinases / genetics. Phosphorylation / genetics. Signal Transduction / genetics

  • Linkoping University Electronic Press. Full text from .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTAC Assay Portal. NCI CPTAC Assay Portal .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • NCI CPTC Antibody Characterization Program. NCI CPTC Antibody Characterization Program .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Dev Cell. 2007 Sep;13(3):391-404 [17765682.001]
  • [Cites] Nat Genet. 1998 Aug;19(4):348-55 [9697695.001]
  • [Cites] Biochem Soc Trans. 1997 Aug;25(3):981-8 [9388586.001]
  • [Cites] EMBO J. 1999 Nov 15;18(22):6211-20 [10562533.001]
  • [Cites] Proc Natl Acad Sci U S A. 2007 May 1;104(18):7564-9 [17452630.001]
  • [Cites] J Mol Biol. 2014 May 15;426(10):2070-81 [24636949.001]
  • [Cites] Int J Cancer. 2007 Oct 15;121(8):1771-8 [17590872.001]
  • [Cites] Cancer Genet Cytogenet. 2003 Jan 1;140(1):45-8 [12550757.001]
  • [Cites] Clin Mol Pathol. 1996 Dec;49(6):M321-30 [16696098.001]
  • [Cites] Oncogene. 2003 Mar 27;22(12):1892-905 [12660825.001]
  • [Cites] PLoS Genet. 2013 Mar;9(3):e1003397 [23555303.001]
  • [Cites] Mol Cell Biol. 2004 Jun;24(12 ):5447-58 [15169906.001]
  • [Cites] Lung Cancer. 2006 Feb;51(2):181-91 [16324768.001]
  • [Cites] Mol Biol Cell. 2001 Apr;12(4):780-94 [11294886.001]
  • [Cites] Mol Cell Biol. 2010 Sep;30(17):4280-92 [20606012.001]
  • [Cites] J Cell Biol. 2011 Jun 27;193(7):1275-88 [21708979.001]
  • [Cites] Mol Cell Biol. 2008 Sep;28(17 ):5184-95 [18573875.001]
  • [Cites] Oncogene. 2000 May 25;19(23 ):2739-44 [10851074.001]
  • [Cites] BMC Genet. 2015 Jul 14;16:80 [26170120.001]
  • [Cites] Int J Cancer. 2007 Apr 1;120(7):1472-81 [17245700.001]
  • [Cites] Genes Chromosomes Cancer. 2005 Jun;43(2):162-71 [15751041.001]
  • [Cites] Cell. 2000 Jan 7;100(1):57-70 [10647931.001]
  • [Cites] BMC Cell Biol. 2014 Mar 11;15:8 [24618359.001]
  • [Cites] Int J Cancer. 2004 Oct 20;112(1):150-4 [15305387.001]
  • [Cites] Annu Rev Cell Dev Biol. 1996;12:463-518 [8970735.001]
  • [Cites] Haematologica. 2010 Mar;95(3):415-23 [20007139.001]
  • [Cites] Annu Rev Cell Dev Biol. 2010;26:315-33 [19575647.001]
  • [Cites] Nature. 2002 Dec 19-26;420(6917):821-4 [12490950.001]
  • [Cites] Cell. 2011 Mar 4;144(5):646-74 [21376230.001]
  • [Cites] Cytoskeleton (Hoboken). 2012 Aug;69(8):555-65 [22736583.001]
  • [Cites] Cancer Res. 2009 Aug 1;69(15):6042-8 [19638584.001]
  • [Cites] J Clin Pathol. 2005 Apr;58(4):343-51 [15790695.001]
  • [Cites] J Cell Sci. 2012 Apr 15;125(Pt 8):1991-2003 [22328521.001]
  • [Cites] Oncol Rep. 2005 Aug;14(2):471-4 [16012732.001]
  • [Cites] J Biol Chem. 2011 Feb 11;286(6):4133-40 [21127070.001]
  • [Cites] Mol Cell Biol. 2008 Jul;28(13):4215-26 [18426911.001]
  • [Cites] Curr Opin Cell Biol. 2000 Oct;12(5):569-74 [10978891.001]
  • [Cites] Cell Metab. 2008 Nov;8(5):344-6 [19046566.001]
  • [Cites] Annu Rev Cell Dev Biol. 1995;11:633-75 [8689571.001]
  • [Cites] Cell Metab. 2008 Nov;8(5):384-98 [19046570.001]
  • [Cites] J Urol. 2002 Apr;167(4):1836-43 [11912444.001]
  • [Cites] Science. 2000 Oct 13;290(5490):337-41 [11030652.001]
  • [Cites] Mol Cell Biol. 2011 May;31(10):2134-50 [21402783.001]
  • [Cites] Annu Rev Physiol. 2003;65:761-89 [12471164.001]
  • [Cites] Cell Death Differ. 2010 Apr;17(4):677-88 [19834495.001]
  • [Cites] Am J Physiol Heart Circ Physiol. 2013 Mar 1;304(5):H687-96 [23262137.001]
  • [Cites] J Biol Chem. 2005 Dec 23;280(51):42300-6 [16239226.001]
  • [Cites] Methods. 2003 Jul;30(3):256-68 [12798140.001]
  • [Cites] Carcinogenesis. 2000 Nov;21(11):2019-26 [11062163.001]
  • [Cites] Dev Cell. 2007 Apr;12(4):487-502 [17419990.001]
  • [Cites] Mol Biol Cell. 2012 Oct;23(20):4065-78 [22918957.001]
  • [Cites] Breast Cancer Res Treat. 2010 Jul;122(1):45-53 [19701705.001]
  • [Cites] J Biol Chem. 1998 May 29;273(22):13375-8 [9593664.001]
  • [Cites] Mol Biol Cell. 2006 Nov;17(11):4856-65 [16971510.001]
  • [Cites] Proc Natl Acad Sci U S A. 2006 Feb 28;103(9):3118-23 [16492791.001]
  • [Cites] Drug Resist Updat. 2002 Dec;5(6):234-48 [12531180.001]
  • (PMID = 27716847.001).
  • [ISSN] 1932-6203
  • [Journal-full-title] PloS one
  • [ISO-abbreviation] PLoS ONE
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / Tumor Suppressor Proteins; EC 2.7.1.- / Phosphatidylinositol 3-Kinases; EC 2.7.11.1 / Proto-Oncogene Proteins c-akt; EC 3.6.1.- / Myosin Type I; EC 3.6.1.3 / MYO1C protein, human
  •  go-up   go-down


5. Al-Habsi HA, Al-Hinai M, Al-Waily A, Al-Sudairy S, de Silva V: Syringocystadenoma papilliferum of the upper lip. Sultan Qaboos Univ Med J; 2014 Nov;14(4):e575-7
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • It was occasionally associated with recurrent ulceration and bleeding and had previously been misdiagnosed and mismanaged.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 25364565.001).
  • [ISSN] 2075-051X
  • [Journal-full-title] Sultan Qaboos University medical journal
  • [ISO-abbreviation] Sultan Qaboos Univ Med J
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Oman
  • [Other-IDs] NLM/ PMC4205074
  • [Keywords] NOTNLM ; Basal Cell Carcinoma / Case Report / Lip / Misdiagnoses / Oman / Skin Neoplasms / Sweat Glands
  •  go-up   go-down


6. Iljin A, Zieliński T, Antoszewski B, Sporny S: Clinicopathological analysis of recurrent basal cell carcinoma of the eyelid. Postepy Dermatol Alergol; 2016 Feb;33(1):42-6
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Clinicopathological analysis of recurrent basal cell carcinoma of the eyelid.
  • INTRODUCTION: Basal cell carcinoma (BCC) is the most common malignant neoplasm of the eyelids and surrounding structures, usually developing in the area of the lower lid and medial canthus.
  • AIM: Clinical and pathological analysis of recurrent BCCs of the eyelids and surrounding structures.
  • MATERIAL AND METHODS: We present clinical and pathological analysis including immunohistochemical reaction to Ki-67 antigen of 19 patients (11 women, 8 men) operated for recurrent BCCs of the eyelids in 2000-2012.
  • Clinical and pathological analysis of patients with recurrent BCC of the eyelids and surrounding structures should be combined with the evaluation of proliferation index Ki-67, which is essential for prognosis and choice of the appropriate therapeutic method.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • (PMID = 26985178.001).
  • [ISSN] 1642-395X
  • [Journal-full-title] Postȩpy dermatologii i alergologii
  • [ISO-abbreviation] Postepy Dermatol Alergol
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Poland
  • [Other-IDs] NLM/ PMC4793053
  • [Keywords] NOTNLM ; Ki-67 antigen / eyelid / recurrent BCC
  •  go-up   go-down


7. Qi XP, Zhao JQ, Chen ZG, Cao JL, Du J, Liu NF, Li F, Sheng M, Fu E, Guo J, Jia H, Zhang YM, Ma JM: RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D. Oncotarget; 2015 Oct 20;6(32):33993-4003
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] RET mutation p.S891A in a Chinese family with familial medullary thyroid carcinoma and associated cutaneous amyloidosis binding OSMR variant p.G513D.
  • There are no reports on the relationship between familial medullary thyroid carcinoma (FMTC) associated with cutaneous amyloidosis (CA) and RET or OSMR/IL31RA gene mutations.
  • In this study, we investigated a Chinese family with FMTC/CA and found a recurrent RET c.2671T>G (p.S891A) mutation in six of 17 family members.
  • Three of the six p.S891A mutation carriers presented with medullary thyroid carcinoma (MTC).
  • Of them, three carriers had no evidence of thyroid/skin or basal serum/stimulated calcitonin abnormalities.
  • In vitro cell proliferation assay indicated that oncogenic activity of RET p.S891A was slightly enhanced by p.R525W, whereas p.R525W alone had no effect on cell proliferation.
  • [MeSH-major] Amyloidosis, Familial / genetics. Carcinoma, Medullary / congenital. Multiple Endocrine Neoplasia Type 2a / genetics. Mutation. Oncostatin M Receptor beta Subunit / genetics. Proto-Oncogene Proteins c-ret / genetics. Skin Diseases, Genetic / genetics. Thyroid Neoplasms / genetics
  • [MeSH-minor] Adolescent. Adult. Aged. Calcitonin / metabolism. Cell Proliferation. Child. China. DNA Mutational Analysis. Family Health. Female. Fluorescent Antibody Technique, Indirect. Genetic Association Studies. Genetic Variation. Genetic Vectors. Germ-Line Mutation. HEK293 Cells. Heterozygote. Humans. Male. Phenotype

  • Genetic Alliance. consumer health - Amyloidosis.
  • Genetic Alliance. consumer health - Amyloidosis Familial.
  • MedlinePlus Health Information. consumer health - Thyroid Cancer.
  • Hazardous Substances Data Bank. Calcitonin .
  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Cancer Res. 2005 Mar 1;65(5):1729-37 [15753368.001]
  • [Cites] Eur J Endocrinol. 1998 Oct;139(4):410-5 [9820617.001]
  • [Cites] Br J Dermatol. 2006 Dec;155(6):1201-8 [17107390.001]
  • [Cites] Am J Hum Genet. 2008 Jan;82(1):73-80 [18179886.001]
  • [Cites] Thyroid. 2008 Jul;18(7):775-82 [18631007.001]
  • [Cites] Hum Mutat. 2009 Apr;30(4):548-56 [19177457.001]
  • [Cites] Thyroid. 2009 Jun;19(6):651-5 [19445625.001]
  • [Cites] Thyroid. 2009 Jun;19(6):565-612 [19469690.001]
  • [Cites] Arch Dermatol. 2009 Jun;145(6):695-9 [19528426.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Jan;95(1):308-13 [19906784.001]
  • [Cites] Ann Surg Oncol. 2010 Jun;17(6):1471-4 [20180029.001]
  • [Cites] J Clin Endocrinol Metab. 2010 Sep;95(9):E92-7 [20554711.001]
  • [Cites] J Med Genet. 2001 Nov;38(11):784-7 [11732489.001]
  • [Cites] Endocr Pract. 2002 Jan-Feb;8(1):19-22 [11939755.001]
  • [Cites] Horm Metab Res. 2002 Apr;34(4):202-6 [11987030.001]
  • [Cites] Clin Endocrinol (Oxf). 2003 Aug;59(2):156-61 [12864791.001]
  • [Cites] J Clin Endocrinol Metab. 2003 Nov;88(11):5438-43 [14602786.001]
  • [Cites] Surgery. 2004 May;135(5):563-4 [15118594.001]
  • [Cites] Cell. 1985 Sep;42(2):581-8 [2992805.001]
  • [Cites] Oncogene. 1988 Nov;3(5):571-8 [3078962.001]
  • [Cites] Clin Endocrinol (Oxf). 1991 Jun;34(6):435-9 [1889128.001]
  • [Cites] Hum Mol Genet. 1993 Jul;2(7):851-6 [8103403.001]
  • [Cites] J Endocrinol Invest. 1994 Mar;17(3):201-4 [7914213.001]
  • [Cites] Science. 1995 Jan 20;267(5196):381-3 [7824936.001]
  • [Cites] J Invest Dermatol. 1996 Jul;107(1):30-3 [8752835.001]
  • [Cites] J Invest Dermatol. 1996 Aug;107(2):215-8 [8757765.001]
  • [Cites] JAMA. 1996 Nov 20;276(19):1575-9 [8918855.001]
  • [Cites] J Clin Endocrinol Metab. 2011 May;96(5):1237-45 [21346073.001]
  • [Cites] PLoS One. 2011;6(5):e20353 [21655256.001]
  • [Cites] Eur J Dermatol. 2012 Jan-Feb;22(1):29-33 [22062952.001]
  • [Cites] Indian J Pathol Microbiol. 2012 Apr-Jun;55(2):170-4 [22771637.001]
  • [Cites] Cell Rep. 2012 Nov 29;2(5):1233-43 [23168260.001]
  • [Cites] J Clin Endocrinol Metab. 2013 Aug;98(8):3149-64 [23744408.001]
  • [Cites] Lancet Oncol. 2014 May;15(6):648-55 [24745698.001]
  • [Cites] J Biosci. 2014 Jun;39(3):505-12 [24845513.001]
  • [Cites] Indian J Med Res. 2014 May;139(5):779-81 [25027091.001]
  • [Cites] Thyroid. 2015 Jun;25(6):567-610 [25810047.001]
  • [Cites] Am J Clin Oncol. 2015 Oct;38(5):508-13 [24064755.001]
  • [Cites] Hum Mutat. 1997;9(2):97-109 [9067749.001]
  • [Cites] Clin Genet. 1997 Feb;51(2):86-90 [9111993.001]
  • [Cites] J Endocrinol Invest. 2005 Sep;28(8):734-7 [16277170.001]
  • (PMID = 26356818.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Publication-type] Journal Article; Research Support, Non-U.S. Gov't
  • [Publication-country] United States
  • [Chemical-registry-number] 0 / OSMR protein, human; 0 / Oncostatin M Receptor beta Subunit; 9007-12-9 / Calcitonin; EC 2.7.10.1 / Proto-Oncogene Proteins c-ret; EC 2.7.10.1 / RET protein, human; Amyloidosis, Primary Cutaneous; Familial medullary thyroid carcinoma
  • [Other-IDs] NLM/ PMC4741820
  • [Keywords] NOTNLM ; OSMR variant / RET mutation / cutaneous amyloidosis / medullary thyroid carcinoma / thyroid neoplasia
  •  go-up   go-down


8. Shome D, Bell D, Esmaeli B: Eyelid carcinoma in patients with systemic lymphoma. J Ophthalmic Vis Res; 2010 Jan;5(1):38-43
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • [Title] Eyelid carcinoma in patients with systemic lymphoma.
  • PURPOSE: To describe a series of patients with Non-Hodgkin's lymphoma (NHL) and concomitant eyelid carcinoma.
  • METHODS: In this non-comparative interventional case series, we retrospectively reviewed the medical records of 5 patients with NHL who developed eyelid carcinoma.
  • Systemic lymphoma had been diagnosed 1 to 72 months prior to development of the eyelid carcinoma.
  • The lesions were basal cell carcinoma in three, and squamous cell carcinoma in two cases.
  • Four patients underwent surgical excision of the carcinoma and one patient was awaiting surgical treatment after completing systemic chemotherapy.
  • Two patients had perineural invasion; one received adjuvant radiotherapy postoperatively but the other did not due to receiving systemic chemotherapy for recurrent NHL.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] JAMA. 1975 Apr 21;232(3):267-9 [47401.001]
  • [Cites] J Natl Cancer Inst. 1978 Aug;61(2):337-40 [277720.001]
  • [Cites] J Natl Cancer Inst. 1992 Sep 16;84(18):1422-7 [1512794.001]
  • [Cites] BMJ. 1995 Jun 10;310(6993):1491-5 [7787593.001]
  • [Cites] Curr Opin Hematol. 2000 Jul;7(4):223-34 [10882178.001]
  • [Cites] J Natl Cancer Inst. 2005 Feb 2;97(3):199-209 [15687363.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2008 Nov-Dec;24(6):444-9 [19033839.001]
  • [Cites] Am J Ophthalmol. 1986 Apr 15;101(4):480-2 [3515953.001]
  • [Cites] Arch Ophthalmol. 1980 Oct;98(10):1771-2 [7000053.001]
  • [Cites] Eur J Haematol. 1994 Oct;53(4):218-22 [7957806.001]
  • [Cites] Br J Cancer. 1996 Dec;74(11):1847-50 [8956805.001]
  • [Cites] Acta Haematol. 1997;98(1):44-6 [9210914.001]
  • [Cites] Int J Cancer. 1999 Mar 1;80(5):641-5 [10048959.001]
  • [Cites] Dermatology. 2001;202(4):359-61 [11455161.001]
  • [Cites] J Am Acad Dermatol. 2002 Jul;47(1):1-17; quiz 18-20 [12077575.001]
  • [Cites] Curr Treat Options Oncol. 2004 Jun;5(3):215-23 [15115650.001]
  • [Cites] Leuk Lymphoma. 2004 Mar;45(3):507-13 [15160912.001]
  • [Cites] Histopathology. 2004 Aug;45(2):162-70 [15279635.001]
  • [Cites] Arch Dermatol. 2004 Aug;140(8):985-8 [15313816.001]
  • [Cites] Oncogene. 2004 Aug 23;23(38):6524-34 [15322522.001]
  • [Cites] Leuk Lymphoma. 2005 Jan;46(1):49-54 [15621780.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):38-42; discussion 42 [15720094.001]
  • [Cites] Leuk Lymphoma. 2005 Jul;46(7):1051-5 [16019557.001]
  • [Cites] Skinmed. 2005 Sep-Oct;4(5):300-4 [16282752.001]
  • [Cites] Australas J Dermatol. 2006 Nov;47(4):231-6 [17034463.001]
  • (PMID = 22737325.001).
  • [ISSN] 2008-2010
  • [Journal-full-title] Journal of ophthalmic & vision research
  • [ISO-abbreviation] J Ophthalmic Vis Res
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] Iran
  • [Other-IDs] NLM/ PMC3380669
  • [Keywords] NOTNLM ; Eyelid Cancer / Immunosuppression / Squamous Cell Carcinoma / Systemic Lymphoma
  •  go-up   go-down


9. Colebatch AJ, Di Stefano L, Wong SQ, Hannan RD, Waring PM, Dobrovic A, McArthur GA, Papenfuss AT: Clustered somatic mutations are frequent in transcription factor binding motifs within proximal promoter regions in melanoma and other cutaneous malignancies. Oncotarget; 2016 Oct 11;7(41):66569-66585
PDF icon [Fulltext service] Download fulltext PDF of this article and others, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • Most cancer DNA sequencing studies have prioritized recurrent non-synonymous coding mutations in order to identify novel cancer-related mutations.
  • We sought to identify clustered somatic mutations (hotspot regions across samples) in functionally annotated regions in melanoma and other cutaneous malignancies (cutaneous squamous cell carcinoma, basal cell carcinoma and Merkel cell carcinoma).
  • Sliding window analyses revealed numerous recurrent clustered hotspot mutations in proximal promoters, with some specific clusters present in up to 25% of cases.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Mod Pathol. 2014 Apr;27(4):516-23 [24030752.001]
  • [Cites] Science. 2015 May 22;348(6237):880-6 [25999502.001]
  • [Cites] Clin Cancer Res. 2013 Sep 1;19(17):4589-98 [23833303.001]
  • [Cites] Mol Cell Biol. 2005 Mar;25(5):1586-95 [15713619.001]
  • [Cites] Mol Cell Biol. 1992 Apr;12(4):1798-804 [1549126.001]
  • [Cites] Oncotarget. 2014 May 30;5(10):2912-7 [24913145.001]
  • [Cites] Nat Genet. 2014 Nov;46(11):1160-5 [25261935.001]
  • [Cites] Database (Oxford). 2014 Sep 29;2014:null [25267794.001]
  • [Cites] Nat Rev Genet. 2011 Dec 06;13(1):59-69 [22143240.001]
  • [Cites] Bioinformatics. 2007 May 15;23(10):1289-91 [17379693.001]
  • [Cites] Nat Genet. 2011 Dec 25;44(2):133-9 [22197931.001]
  • [Cites] Nature. 2016 Apr 14;532(7598):259-63 [27075100.001]
  • [Cites] Science. 2015 May 29;348(6238):1036-9 [25977370.001]
  • [Cites] Science. 1994 Mar 11;263(5152):1438-40 [8128226.001]
  • [Cites] Genes Dev. 2015 May 1;29(9):948-60 [25934506.001]
  • [Cites] Nat Biotechnol. 2014 Jan;32(1):71-5 [24336318.001]
  • [Cites] Cell. 2015 Jun 18;161(7):1681-96 [26091043.001]
  • [Cites] Cell Cycle. 2013 May 15;12(10):1637-8 [23603989.001]
  • [Cites] N Engl J Med. 2015 Nov 12;373(20):1926-36 [26559571.001]
  • [Cites] Nature. 2007 Mar 8;446(7132):153-8 [17344846.001]
  • [Cites] Nature. 2016 Apr 14;532(7598):264-7 [27075101.001]
  • [Cites] Nat Genet. 2015 Oct;47(10):1194-9 [26343386.001]
  • [Cites] Mol Cancer Res. 2015 Aug;13(8):1218-26 [26082173.001]
  • [Cites] Nature. 2012 Sep 6;489(7414):57-74 [22955616.001]
  • [Cites] Nat Genet. 2012 Sep;44(9):1006-14 [22842228.001]
  • [Cites] PLoS One. 2013 Nov 18;8(11):e80354 [24260374.001]
  • [Cites] Science. 2006 Oct 13;314(5797):268-74 [16959974.001]
  • [Cites] Nucleic Acids Res. 2013 Jan;41(Database issue):D195-202 [23175603.001]
  • [Cites] Nature. 2013 Jul 11;499(7457):214-8 [23770567.001]
  • [Cites] Clin Cancer Res. 2014 Dec 15;20(24):6582-92 [25303977.001]
  • [Cites] Cell. 2012 Jul 20;150(2):251-63 [22817889.001]
  • [Cites] Elife. 2015 Jul 21;4:null [26194807.001]
  • [Cites] Photochem Photobiol. 2015 Jan-Feb;91(1):15-26 [25354245.001]
  • [Cites] Nature. 2012 May 09;485(7399):502-6 [22622578.001]
  • [Cites] Oncotarget. 2015 Nov 3;6(34):35922-30 [26416425.001]
  • [Cites] J Clin Endocrinol Metab. 2013 Sep;98(9):E1562-6 [23833040.001]
  • [Cites] Nucleic Acids Res. 2000 Oct 15;28(20):3991-8 [11024179.001]
  • [Cites] Clin Chem. 2013 Sep;59(9):1376-83 [23649127.001]
  • [Cites] J Biol Chem. 2002 Apr 5;277(14 ):11845-52 [11805105.001]
  • [Cites] J Mol Biol. 1995 Jun 16;249(4):714-28 [7602584.001]
  • [Cites] Proc Int Conf Intell Syst Mol Biol. 1994;2:28-36 [7584402.001]
  • [Cites] Science. 2013 Feb 22;339(6122):959-61 [23348503.001]
  • [Cites] Nucleic Acids Res. 2004 Jan 1;32(Database issue):D493-6 [14681465.001]
  • [Cites] Cancer Cell. 2015 Mar 9;27(3):342-53 [25759020.001]
  • [Cites] Cancer. 1999 Jul 15;86(2):288-99 [10421265.001]
  • [Cites] Nucleic Acids Res. 2012 Aug;40(15):e115 [22730293.001]
  • [Cites] Ann Surg Oncol. 2010 Jun;17(6):1471-4 [20180029.001]
  • [Cites] Science. 2013 Feb 22;339(6122):957-9 [23348506.001]
  • [Cites] Essays Biochem. 2013;54:1-16 [23829523.001]
  • [Cites] Science. 2015 Feb 27;347(6225):1006-10 [25722414.001]
  • [Cites] Nucleic Acids Res. 1996 Sep 15;24(18):3499-506 [8836174.001]
  • [Cites] Nat Genet. 2014 Dec;46(12):1258-63 [25383969.001]
  • [Cites] BMC Cancer. 2011 Jun 24;11:265 [21702907.001]
  • [Cites] Genome Biol. 2007;8(2):R24 [17324271.001]
  • [Cites] Nat Genet. 2011 May;43(5):442-6 [21499247.001]
  • [Cites] EMBO J. 1996 Feb 1;15(3):675-83 [8599951.001]
  • [Cites] Proc Natl Acad Sci U S A. 2013 Aug 13;110(33):13481-6 [23901115.001]
  • [Cites] Nat Commun. 2014 Feb 26;5:3401 [24569790.001]
  • [Cites] Nat Biotechnol. 2013 Mar;31(3):213-9 [23396013.001]
  • [Cites] J Natl Cancer Inst. 2014 Sep 13;106(9):null [25217772.001]
  • (PMID = 27611953.001).
  • [ISSN] 1949-2553
  • [Journal-full-title] Oncotarget
  • [ISO-abbreviation] Oncotarget
  • [Language] eng
  • [Publication-type] Journal Article
  • [Publication-country] United States
  • [Keywords] NOTNLM ; gene promoter / melanoma / non-coding mutations / transcription factors / ultraviolet radiation
  •  go-up   go-down


10. Allen RC: Surgical Management of Periocular Cancers: High- and Low-Risk Features Drive Treatment. Curr Oncol Rep; 2017 Sep;19(9):57
PDF icon [Fulltext service] Get downloadable fulltext PDFs of articles closely matching to this article, as many as you want.

  • [Source] The source of this record is MEDLINE®, a database of the U.S. National Library of Medicine.
  • RECENT FINDINGS: Mohs excision of basal cell carcinoma and squamous cell carcinoma continues to provide the greatest success in complete excision of the cancer, especially in those cases of high-risk disease including medial canthal location and recurrent disease.
  • Sentinel lymph node biopsy has proven useful in the assessment of early regional metastasis in sebaceous cell carcinoma, melanoma, and Merkel cell carcinoma.

  • [Email] Email this result item
    Email the results to the following email address:   [X] Close
  • [Cites] Eye (Lond). 2015 Jul;29(7):958-63 [25998946.001]
  • [Cites] Am J Ophthalmol. 2016 Nov;171:67-74 [27590119.001]
  • [Cites] Br J Plast Surg. 2004 Sep;57(6):485-501 [15308394.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2012 Jul-Aug;28(4):277-81 [22785585.001]
  • [Cites] Dermatol Surg. 2017 Feb;43(2):281-286 [28165350.001]
  • [Cites] N Engl J Med. 2012 Jul 12;367 (2):107-14 [22663011.001]
  • [Cites] Ophthalmology. 1996 Jun;103(6):937-41 [8643251.001]
  • [Cites] Eur J Ophthalmol. 2014 Jul-Aug;24(4):476-82 [24338583.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2016 Sep-Oct;32(5):371-3 [26325381.001]
  • [Cites] Ophthalmology. 2016 Jan;123(1):203-8 [26520170.001]
  • [Cites] J Am Acad Dermatol. 1995 Dec;33(6):923-36; quiz 937-40 [7490362.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2014 Jan-Feb;30(1):15-9 [24398481.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2010 Mar-Apr;26(2):100-2 [20305508.001]
  • [Cites] Am J Ophthalmol. 1999 Nov;128(5):635-6 [10577535.001]
  • [Cites] Orbit. 2010 Apr;29(2):83-7 [20394545.001]
  • [Cites] Am J Clin Dermatol. 2016 Oct;17 (5):491-508 [27358187.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2014 Dec;28(12):1751-5 [25564683.001]
  • [Cites] Orbit. 2003 Dec;22(4):235-8 [14685896.001]
  • [Cites] Dermatol Surg. 2007 Apr;33(4):433-9; discussion 440 [17430377.001]
  • [Cites] JAMA Ophthalmol. 2014 Feb;132(2):197-204 [24287584.001]
  • [Cites] Future Oncol. 2015 Nov;11(22):3003-10 [26437207.001]
  • [Cites] Br J Ophthalmol. 2014 Apr;98(4):498-501 [24429279.001]
  • [Cites] Br J Ophthalmol. 2013 Nov;97(11):1459-63 [24037608.001]
  • [Cites] J Craniofac Surg. 2017 Jan;28(1):e84-e87 [27906855.001]
  • [Cites] Int Ophthalmol. 2016 Oct;36(5):681-90 [26830096.001]
  • [Cites] Orbit. 2010 Jun;29(3):140-5 [20497079.001]
  • [Cites] JAMA Ophthalmol. 2013 Oct;131(10):1364-6 [23907144.001]
  • [Cites] Ophthalmology. 2001 Sep;108(9):1575-9 [11535453.001]
  • [Cites] Br J Ophthalmol. 2005 Sep;89(9):1201-4 [16113382.001]
  • [Cites] JAMA Ophthalmol. 2013 Dec;131(12):1591-4 [24136169.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2015 Nov-Dec;31(6):463-6 [25675162.001]
  • [Cites] Ophthalmology. 2010 Dec;117(12 ):2424-9 [20591492.001]
  • [Cites] Ophthalmology. 2003 Jul;110(7):1403-7 [12867399.001]
  • [Cites] Acta Ophthalmol. 2017 Jun;95(4):e323-e328 [27775232.001]
  • [Cites] Br J Ophthalmol. 2015 Jul;99(7):909-13 [25595178.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2013 Mar-Apr;29(2):87-92 [23446297.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2011 Sep-Oct;27(5):356-9 [21629141.001]
  • [Cites] JAMA Ophthalmol. 2014 Aug;132(8):1025-8 [24969841.001]
  • [Cites] Ophthalmology. 2015 Jul;122(7):1512-6 [25972255.001]
  • [Cites] Am J Otolaryngol. 2013 Sep-Oct;34(5):373-7 [23415573.001]
  • [Cites] Ophthalmology. 2008 Jan;115(1):195-201 [17531320.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2012 May-Jun;28(3):181-3 [22460673.001]
  • [Cites] Dermatol Surg. 2005 Jan;31(1):38-42; discussion 42 [15720094.001]
  • [Cites] N Engl J Med. 2012 Jun 7;366(23 ):2180-8 [22670904.001]
  • [Cites] Ophthalmology. 2004 Apr;111(4):631-6 [15051193.001]
  • [Cites] Br J Ophthalmol. 2011 Dec;95(12):1679-81 [20829320.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2013 Jan-Feb;29(1):6-10 [23034693.001]
  • [Cites] Curr Opin Ophthalmol. 2012 Sep;23 (5):439-42 [22828167.001]
  • [Cites] Ophthalmology. 2002 Nov;109(11):2129-33 [12414427.001]
  • [Cites] Ophthalmology. 1997 Mar;104(3):479-84 [9082276.001]
  • [Cites] Jpn J Ophthalmol. 2014 Jul;58(4):327-33 [24763914.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2016 Jan-Feb;32(1):35-9 [25675161.001]
  • [Cites] J Am Acad Dermatol. 2014 Apr;70(4):630-6 [24433872.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2017 Jan/Feb;33(1):17-21 [26836812.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2003 Nov;19(6):477-9 [14625495.001]
  • [Cites] Surv Ophthalmol. 2005 Mar-Apr;50(2):103-22 [15749305.001]
  • [Cites] Ophthalmology. 2005 Apr;112(4):717-23 [15808267.001]
  • [Cites] Ophthalmology. 2012 May;119(5):1078-82 [22330966.001]
  • [Cites] Semin Oncol. 2015 Dec;42 Suppl 3:S12-9 [26598055.001]
  • [Cites] Ophthalmology. 2004 Dec;111(12):2151-7 [15582067.001]
  • [Cites] Br J Ophthalmol. 2009 Apr;93(4):474-6 [19060015.001]
  • [Cites] Dermatol Surg. 1997 Oct;23(10):929-33 [9357504.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2017 Mar/Apr;33(2):101-105 [26974419.001]
  • [Cites] Ophthal Plast Reconstr Surg. 2014 Mar-Apr;30(2):105-9 [24481504.001]
  • [Cites] Cancer. 1997 Sep 1;80(5):881-5 [9307187.001]
  • [Cites] Clin Exp Ophthalmol. 2009 May;37(4):352-6 [19594560.001]
  • [Cites] World J Clin Cases. 2014 Sep 16;2(9):432-8 [25232546.001]
  • [Cites] Int Ophthalmol Clin. 2015 Fall;55(4):73-9 [26322427.001]
  • [Cites] JAMA Dermatol. 2016 Apr;152(4):419-28 [26762219.001]
  • [Cites] Am Soc Clin Oncol Educ Book. 2015;:e513-8 [25993217.001]
  • [Cites] Br J Ophthalmol. 2011 Jun;95(6):890-2 [21378006.001]
  • [Cites] Asia Pac J Ophthalmol (Phila). 2015 Jul-Aug;4(4):221-7 [26147013.001]
  • [Cites] J Eur Acad Dermatol Venereol. 2014 Sep;28(9):1141-9 [24612407.001]
  • (PMID = 28735439.001).
  • [ISSN] 1534-6269
  • [Journal-full-title] Current oncology reports
  • [ISO-abbreviation] Curr Oncol Rep
  • [Language] eng
  • [Publication-type] Journal Article; Review
  • [Publication-country] United States
  • [Keywords] NOTNLM ; Basal cell carcinoma / Eyelid / Melanoma / Merkel cell carcinoma / Sebaceous carcinoma / Squamous cell carcinoma
  •  go-up   go-down






Advertisement